Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million

Reuters

Yesterday

Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million

Sinopharm published a 2025 annual results presentation reporting business revenue of RMB575.17 billion, up 1.62%.
Net profits were RMB10.83 billion, up 3.94%, while net profits attributable to owners of the parent were RMB7.16 billion, up 1.5%.
Gross profit margin was 7.25% (down 0.32 percentage points) and net profit margin was 1.88% (up 0.1 percentage points).
Segment revenue included pharmaceutical distribution of RMB435.39 billion (up 2.06%) and medical device distribution of RMB115.54 billion (down 2.02%).
Retail pharmacy revenue was RMB38.38 billion (up 6.67%) and management said wholesale-retail integration and a dual-brand strategy supported growth, while it managed lower-efficiency device businesses with long payment terms to reduce risk.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2621403507"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621403507\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621403507?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 08:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621403507","market":"fut","top_or_hot":-1,"title":"Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sinopharm published a 2025 annual results presentation reporting business revenue of RMB575.17 billion, up 1.62%.\n        </li>\n<li>\n          Net profits were RMB10.83 billion, up 3.94%, while net profits attributable to owners of the parent were RMB7.16 billion, up 1.5%.\n        </li>\n<li>\n          Gross profit margin was 7.25% (down 0.32 percentage points) and net profit margin was 1.88% (up 0.1 percentage points).\n        </li>\n<li>\n          Segment revenue included pharmaceutical distribution of RMB435.39 billion (up 2.06%) and medical device distribution of RMB115.54 billion (down 2.02%).\n        </li>\n<li>\n          Retail pharmacy revenue was RMB38.38 billion (up 6.67%) and management said wholesale-retail integration and a dual-brand strategy supported growth, while it managed lower-efficiency device businesses with long payment terms to reduce risk.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SHTDF\">Sinopharm Group Co. Ltd.</a> published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 08:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sinopharm published a 2025 annual results presentation reporting business revenue of RMB575.17 billion, up 1.62%.\n        </li>\n<li>\n          Net profits were RMB10.83 billion, up 3.94%, while net profits attributable to owners of the parent were RMB7.16 billion, up 1.5%.\n        </li>\n<li>\n          Gross profit margin was 7.25% (down 0.32 percentage points) and net profit margin was 1.88% (up 0.1 percentage points).\n        </li>\n<li>\n          Segment revenue included pharmaceutical distribution of RMB435.39 billion (up 2.06%) and medical device distribution of RMB115.54 billion (down 2.02%).\n        </li>\n<li>\n          Retail pharmacy revenue was RMB38.38 billion (up 6.67%) and management said wholesale-retail integration and a dual-brand strategy supported growth, while it managed lower-efficiency device businesses with long payment terms to reduce risk.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SHTDF\">Sinopharm Group Co. Ltd.</a> published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0640798160.USD","symbol_name":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL5kWYpj:1","article_id":"2621403507","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621403507","pubTimestamp":1774227097,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million. Sinopharm published a 2025 annual results presentation reporting business revenue of RMB575.17 billion, up 1.62%.Net profits were RMB10.83 billion, up 3.94%, while net profits attributable to owners of the parent were RMB7.16 billion, up 1.5%.Gross profit margin was 7.25%  and net profit margin was 1.88% .Segment revenue included pharmaceutical distribution of RMB435.39 billion  and medical device distribution of RMB115.54 billion .Retail pharmacy revenue was RMB38.38 billion  and management said wholesale-retail integration and a dual-brand strategy supported growth, while it managed lower-efficiency device businesses with long payment terms to reduce risk.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0640798160.USD":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","01099":"国药控股","BK1197":"保健护理产品经销商","LU1115378108.SGD":"Eastspring Investments - Global Emerging Markets Dynamic AS SGD","BK1500":"做空集合股","BK1515":"抗疫概念"},"translate_title":"国药控股2025财年净利润增长3.94%至人民币108.34亿元，经营活动净现金增长22.45%至人民币141.38亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":0.9},"content_text":"Sinopharm FY2025 net profit rose 3.94% to RMB 10,834 million as net cash from operating activities climbed 22.45% to RMB 14,138 million\n    \n\n\n          Sinopharm published a 2025 annual results presentation reporting business revenue of RMB575.17 billion, up 1.62%.\n        \n\n          Net profits were RMB10.83 billion, up 3.94%, while net profits attributable to owners of the parent were RMB7.16 billion, up 1.5%.\n        \n\n          Gross profit margin was 7.25% (down 0.32 percentage points) and net profit margin was 1.88% (up 0.1 percentage points).\n        \n\n          Segment revenue included pharmaceutical distribution of RMB435.39 billion (up 2.06%) and medical device distribution of RMB115.54 billion (down 2.02%).\n        \n\n          Retail pharmacy revenue was RMB38.38 billion (up 6.67%) and management said wholesale-retail integration and a dual-brand strategy supported growth, while it managed lower-efficiency device businesses with long payment terms to reduce risk.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}